iShares NASDAQ US Biotechnology UCITS ETF (LON:BTEE)

Assets	25.52M
Expense Ratio	0.35%
PE Ratio	20.80
Dividend (ttm)	0.02
Dividend Yield	0.47%
Ex-Dividend Date	Dec 12, 2024
Payout Frequency	Semi-Annual
Payout Ratio	n/a
1-Year Return	-8.43%

Volume	15,580
Open	5.83
Previous Close	5.97
Day's Range	5.76 - 5.83
52-Week Low	5.22
52-Week High	7.20
Beta	0.82
Holdings	273
Inception Date	Mar 6, 2018

About BTEE

iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: London Stock Exchange
• Ticker Symbol: BTEE
• Provider: iShares
• Index Tracked: NASDAQ Biotechnology Index

Performance

BTEE had a total return of -8.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.13%.

Top 10 Holdings

47.76% of assets

Name	Symbol	Weight
Vertex Pharmaceuticals Incorporated	VRTX	8.97%
Amgen Inc.	AMGN	7.84%
Gilead Sciences, Inc.	GILD	7.79%
Regeneron Pharmaceuticals, Inc.	REGN	6.97%
AstraZeneca PLC	AZN	4.52%
Alnylam Pharmaceuticals, Inc.	ALNY	3.60%
argenx SE	ARGX	2.23%
Summit Therapeutics Inc.	SMMT	2.20%
Biogen Inc.	BIIB	1.94%
Sanofi	SNY	1.71%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 12, 2024	£0.0089	Dec 27, 2024
Jun 13, 2024	£0.01372	Jun 26, 2024
Dec 14, 2023	£0.00846	Dec 29, 2023
Jun 15, 2023	£0.01113	Jun 28, 2023
Dec 15, 2022	£0.00851	Dec 30, 2022
Jun 16, 2022	£0.01339	Jun 29, 2022